Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | -1.94% | 88.65 | 1.3% | $796.69m | |
| AMGN | Amgen Inc. | -0.76% | 185.50 | 1.2% | $630.51m | |
| GILD | Gilead Sciences, Inc. | -2.14% | 65.55 | 0.9% | $497.34m | |
| BIIB | Biogen Inc. | -4.17% | 321.17 | 1.3% | $426.56m | |
| ILMN | Illumina, Inc. | -1.77% | 296.88 | 3.5% | $314.34m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.92% | 418.62 | 2.6% | $301.49m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -2.55% | 183.06 | 1.9% | $262.15m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.76% | 127.55 | 2.0% | $232.43m | |
| SRPT | Sarepta Therapeutics, Inc. | -2.87% | 136.54 | 15.4% | $150.79m | |
| A | Agilent Technologies, Inc. | -0.83% | 77.91 | 1.6% | $143.97m | |
| EXAS | Exact Sciences Corporation | -0.42% | 83.28 | 25.3% | $128.91m | |
| INCY | Incyte Corporation | -0.49% | 83.33 | 2.5% | $114.75m | |
| ARRY | Array BioPharma Inc. | -1.99% | 22.71 | 8.2% | $107.63m | |
| EXEL | Exelixis, Inc. | -0.09% | 21.22 | 6.4% | $83.96m | |
| NBIX | Neurocrine Biosciences, Inc. | -2.58% | 77.31 | 5.1% | $78.49m |
Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. The company has designed two products candidates: Viaskin Peanut and Viaskin Milk. DBV Technologies was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.